Company Profile

Titan Pharmaceuticals Inc (AKA:TTNP)
Profile last edited on: 2/22/2022            CAGE: 47F74            UEI: E6BMASC5QBS9

Proprietary therapeutics for treatment of serious medical disorders
Year Founded
1992
1st Award Year
1999
Latest Award
2011
Program Status
Inactive
Popularity Index

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

400 Oyster Point Boulevard Suite 505
South San Francisco, CA 94080
   (650) 244-4990
   busdev@titanpharm.com
   www.titanpharm.com
Multiple Locations:   
Congressional District:   14
County:   San Mateo

Public Profile

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) - previously OTC:TTNP - is a biopharmaceutical company developing proprietary therapeutics primarily for treatment of central nervous system (CNS) disorders. Titan’s innovative drug delivery platform - ProNeura®, - is advancing treatment of select chronic diseases by delivering low-dose, non-fluctuating medication levels for up to one year following a single subdermal insertion procedure. Titan’s innovative drug delivery platform - ProNeura® - is advancing the treatment of select chronic diseases by delivering low-dose, non-fluctuating medication levels for up to one year following a single subdermal insertion procedure. Company had been focused on clinical development of: Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders; and Spheramine for the treatment of advanced Parkinson’s disease.Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson’s disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders. Interesting also to note that firm has considerable NIH financial support (post 2011) for projects that are NOT SBIR funded.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : TTNP
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Louis R Bucalo -- Founder and former CEO

  Kate Devarney -- President and Chief Operating Officer

  Richard C Allen -- Executive Vice President and Chief Financial Officer

  Katherine L Beebe -- Exec. VP and Chief Devel. Officer

  Sunial R Bhonsle -- Former Chief Executive Officer

  Rajesh A Patel -- Senior VP, Manufacturing Operations

  Marc Rubin -- Exec. Chairman and Member of Exec. Committee

  Joe Schrei -- Executive Director Commercial Operations

  Sunil P Sreedharan